---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-019520"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:52:42.792264+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones

## Summary
- Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.
- Janux responsible for preclinical through IND; BMS handles later development and commercialization.
- Tiered royalties on global net sales: high-single to low-double digit percentages.
- Collaboration validates Janux's TRACTr/TRACIr/ARM platforms for solid tumor oncology.

## SEC filing metadata
- accession: 0001193125-26-019520
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/0001193125-26-019520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/janx-20260121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-019520
- JSON: https://secwatch.observer/filing/0001193125-26-019520.json
- Plain text: https://secwatch.observer/filing/0001193125-26-019520.txt

## Key facts
- Material Agreements
  Janux Therapeutics, Inc. entered into Collaboration Agreement with Bristol-Myers Squibb Company valued at upfront payment of $15 million (effective 2026-01-21).
  - Action: entry
  - Agreement: license
  - Counterparty: Bristol-Myers Squibb Company
  - Value: upfront payment of $15 million
  - Effective: 2026-01-21
  source text: On January 21, 2026, Janux Therapeutics, Inc. (“Janux” or the “Company”) and Bristol-Myers Squibb Company (“BMS”) entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types (the “Collaboration Target”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/0001193125-26-019520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.